Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4018
Abstract: 4018 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited treatment options. EBC-129 is a first in class MMAE-linked ADC against N256-glycosylated CEACAM5/6 antigen. Pre-screening data shows 73% of PDAC express surface antigen… read more here.
Keywords: treatment; ductal adenocarcinoma; adenocarcinoma pdac; ebc 129 ... See more keywords